NCT02788136

Brief Summary

The study design included six visits. During the first visit (visit 0), the subjects underwent physical examination(height, weight, body mass index (BMI), arm span, and upper segment measurement) and testicular ultrasound (US) for the calculation of testicular volume. At 0800 h of day 0, all subjects provided a basal blood sample immediately followed by a single intramuscular injection of hCG of 5000 IU. Further five visits were performed each of five following consecutive days after the hCG injection. A blood sample was taken at each visit after an overnight fast

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Feb 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2012

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2014

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

May 30, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 2, 2016

Completed
Last Updated

June 7, 2016

Status Verified

June 1, 2016

Enrollment Period

2.4 years

First QC Date

May 30, 2016

Last Update Submit

June 6, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Testosterone

    Using mass spectrometry

    visit 1 (Day 1)

Secondary Outcomes (7)

  • Testicular volume

    visit 0 (Baseline)

  • Steroids

    Visit 0 (Baseline)

  • Steroids

    Visit 1 (Day 1)

  • Steroids

    Visit 2 (Day 2)

  • Steroids

    Visit 3 (Day 3)

  • +2 more secondary outcomes

Study Arms (2)

Klinefelter syndrome

EXPERIMENTAL

13 men with diagnosis of Klinefelter syndrome were stimulated with human chorionic gonadotropin (hCG)

Drug: human chorionic gonadotropin

Control

ACTIVE COMPARATOR

12 healthy age-related men were stimulated with human chorionic gonadotropin (hCG)

Drug: human chorionic gonadotropin

Interventions

At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU

Also known as: hCG
ControlKlinefelter syndrome

Eligibility Criteria

Age18 Years - 40 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Klinefelter syndrome diagnosis at kariotype evaluation for the study group
  • Healthy age-matched men in the control group

You may not qualify if:

  • previous or ongoing androgen therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AziendaUSLModena

Modena, 41126, Italy

Location

Related Publications (1)

  • Belli S, Santi D, Leoni E, Dall'Olio E, Fanelli F, Mezzullo M, Pelusi C, Roli L, Tagliavini S, Trenti T, Granata AR, Pagotto U, Pasquali R, Rochira V, Carani C, Simoni M. Human chorionic gonadotropin stimulation gives evidence of differences in testicular steroidogenesis in Klinefelter syndrome, as assessed by liquid chromatography-tandem mass spectrometry. Eur J Endocrinol. 2016 Jun;174(6):801-11. doi: 10.1530/EJE-15-1224.

    PMID: 27188454BACKGROUND

MeSH Terms

Conditions

Klinefelter Syndrome

Interventions

Chorionic Gonadotropin

Condition Hierarchy (Ancestors)

Sex Chromosome Disorders of Sex DevelopmentDisorders of Sex DevelopmentUrogenital AbnormalitiesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesSex Chromosome DisordersChromosome DisordersCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGenetic Diseases, InbornGonadal DisordersEndocrine System DiseasesHypogonadism

Intervention Hierarchy (Ancestors)

GonadotropinsPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPlacental HormonesPeptidesAmino Acids, Peptides, and ProteinsPregnancy ProteinsProteins

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ordinary Professor

Study Record Dates

First Submitted

May 30, 2016

First Posted

June 2, 2016

Study Start

February 1, 2012

Primary Completion

July 1, 2014

Study Completion

July 1, 2014

Last Updated

June 7, 2016

Record last verified: 2016-06

Locations